Pharmerging Market Overview
Pharmerging is the name given to a collection of nations with rapid growth and limited market share in the pharmaceutical sector. China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, and other are just a few important pharmerging markets regions. Based on rates of economic growth, pharmaceutical markets have been split into three categories. Tier I includes China, which dominated the international pharmaceutical market as a result of substantial public healthcare spending. Brazil, India, and Russia make up Tier II. These nations all have ageing populations, a growth in consumer awareness, and pro-business legislation. Indonesia, Thailand, Mexico, Turkey, Egypt, Vietnam, and South Africa are among the Tier III nations with the smallest market shares among developing nations. The Global Pharmerging Market size accounted for US$ 971.94 billion in 2020 and is estimated to be US$ 4426.72 billion by 2030 and is anticipated to register a CAGR of 6.10%.
Pharmerging Market Dynamics
Increased private hospital numbers
The growth of the global pharmaceutical business is now being driven by increased private hospital numbers and rising healthcare spending. The high prevalence of several chronic diseases and rising consumer knowledge of methods for early disease detection and treatment are also contributing to the market's expansion. Additionally, the ageing population, which is more susceptible to serious illnesses like dementia, hypertension, cardiac failure, etc., is boosting demand for pharmaceuticals.
Most important factor driving the rise in pharmerging markets is the increasing demand for generics brought on by problems with affordability. Favorable government policies supporting localization are anticipated to act as pull factors for generic product producers rather than original product makers. In varied ways around the world, the ageing population is having an impact on this sector. One in six people will reportedly be older than 60 by the year 2030, according to estimates. By 2050, there will be 330 million older people living in China, while there will be 277 million older people living in India. Dementia, hypertension, and cardiac failure are the diseases that affect older people the most frequently. These illnesses need ongoing, protracted therapy. Due to the growing elderly population, there is also a higher need for second care and home healthcare. In nations like India, China, and Brazil, the number of these institutions has increased. Government funding or private funding may be used to support these facilities. The government of Tier I and Tier II have also increased healthcare spending and are implementing supportive policies in order to reduce the cost of treatment for chronic diseases.
Pharmerging Market Segmentation
The Global Pharmerging Market is segmented based on product type, economy, indication, distribution channel and region.
Product Type Insights
On the basis of Product Type, the Global Pharmerging Market is segmented into Pharmaceuticals, Healthcare and Others (IT and Record Management). The majority of the market share in the healthcare sector of developing countries is held by the pharmaceutical segments. By 2025, it is anticipated that generic prescription medications would hold a market share of more than 70 percent. The growth of the pharmaceutical business is anticipated to be driven by this category of generic prescription drugs. The price sensitivity of these countries and increasing out-of-pocket healthcare expenditure is expected to boost the generic prescription drugs market.
Economy Insights
On the basis of Economy, the target market is segmented into Tier-1, Tier-2 and Tier-3. In 2020, Tier I is predicted to have the largest healthcare market among developing nations, and it is anticipated to grow at a profitable pace during the projection period. Global pharmerging market growth is anticipated to be driven by Tier I. India is anticipated to be the Tier II countries' growth engine. As of 2020, Brazil had the largest market share. South Africa and Russia are also included in Tier II.
Indication Insights
Based on Indication, the target market is segmented into Lifestyle Disease, Cancers & Autoimmune Diseases and Infectious Disease.
Distribution Channel Insights
Based on Distribution Channel, the target market is segmented into Hospitals, Clinics, Retail Pharmacies, E-Commerce and Drug Stores.
Regional Insights:
Global Pharmerging Market size accounted for US$ 971.94 billion in 2020 and is estimated to be US$ 4426.72 billion by 2030 and is anticipated to register a CAGR of 16.5%. On region the Global Pharmerging Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically, Asia Pacific dominates the market due to the increasing rate of urbanization and the growing patient base. This will fuel the total expansion of this market in the upcoming years, along with the rise in patients who are being diagnosed with autoimmune, lifestyle, and cancer disorders. China emerged as the main country among those contributing to the expansion of the regional market. Additionally, due to the extensive research and development facilities and growing public knowledge of the healthcare facilities available in the aforementioned locations, the markets in Latin America and Europe have also produced significant profits.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2030 |
|
Market Segmentation |
By Product – Pharmaceuticals, Healthcare and Others (IT and Record Management) By Economy– Tier-1, Tier-2 and Tier-3 By Indication– Lifestyle Disease, Cancers & Autoimmune Diseases and Infectious Disease By Distribution Channel– Hospitals, Clinics, Retail Pharmacies, E-Commerce and Drug Stores |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Recent Development:
- In 2022, the generic counterpart of Tranxene is ANI's Clorazepate Dipotassium Tablets, a reference-listed drug (RLD). According to IQVIA/IMS Health, a renowned provider of healthcare data and analytics, the current annual U.S. market for clorazepate dipotassium tablets is roughly $25.8 million.
- In January 2017, Sanofi and Boehringer Ingelheim (BI) agreed to a strategic transaction in which BI's consumer healthcare business and Sanofi's animal health division (Merial) would be exchanged.
Global Pharmerging Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Pharmerging Market Key Players
The leading players operating in the Global Pharmerging Market includes
- Sanofi S.A. is a French-based international healthcare corporation with its headquarters in Paris.
- Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City.
- AstraZeneca Plc is a worldwide pharmaceutical and biotechnology firm with British and Swedish roots. Its headquarters are located in England.
- GlaxoSmithKline Plc a British multinational pharmaceutical corporation with its global headquarters in London, formerly known as GlaxoSmithKline plc.
- F. Hoffmann-La Roche AG a multinational healthcare corporation based in Switzerland, Roche is more popularly known. It has two business segments: pharmaceuticals and diagnostics. Shares of Roche Holding AG, its holding company, are traded on the SIX Swiss Exchange.
- Eli Lilly and Company is a multinational American pharmaceutical corporation with its headquarters in Indianapolis, Indiana.
- Johnson & Johnson is an American global firm established in 1886 that creates consumer packaged goods, pharmaceuticals, and medical equipment.
- Abbott Laboratories is a worldwide American firm that manufactures medical equipment and provides healthcare, with its headquarters in Abbott Park, Illinois.
- Novartis AG is a Swiss-based global healthcare organisation that offers solutions to meet the changing demands of patients around the world.
- Teva Pharmaceutical Limited is a large, international pharmaceutical firm based in Petah Tikva, Israel.
Pharmerging Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Pharmerging Market
- Key Questions this Study will Answer
- Market Snippet, By Product Type
- Market Snippet, By Economy
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Pharmerging Market, By Product, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Pharmaceuticals
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Healthcare
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Pharmerging Market, By Economy , 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Tier-1
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Tier-2
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Tier-3
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Pharmerging Market, By Indication, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Lifestyle Disease
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Cancer & Autoimmune Disease
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Infectious Disease
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Pharmerging Market, By Distribution Channel, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Clinincs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Retail Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- E-Commerce
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Drug Stores
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Pharmerging Market, By Region, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Economy, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Indication, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Economy, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Indication, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Economy, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Indication, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Economy, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Indication, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Economy, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Indication, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- F. Hoffmann-La Roche AG (Roche AG)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Teva Pharmaceutical Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
The Last Word
-
- Future Impact
- About Us
- Contact
FAQs
The Global Pharmerging Market is segmented based on product, economy, indication, distribution channel and region.
The growth of the global pharmaceutical business is now being driven by increased private hospital numbers and rising healthcare spending.
Asia Pacific dominates the market due to the increasing rate of urbanization and the growing patient base.
Key players in the global Pharmerging Market include Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.